184 related articles for article (PubMed ID: 33734109)
41. Expression of DNA mismatch repair proteins MLH1, MSH2, and MSH6 in recurrent glioblastoma.
Stark AM; Doukas A; Hugo HH; Hedderich J; Hattermann K; Maximilian Mehdorn H; Held-Feindt J
Neurol Res; 2015 Feb; 37(2):95-105. PubMed ID: 24995467
[TBL] [Abstract][Full Text] [Related]
42. Importance of MutL homologue MLH1 and MutS homologue MSH2 expression in Turkish patients with sporadic colorectal cancer.
Erdamar S; Ucaryilmaz E; Demir G; Karahasanoglu T; Dogusoy G; Dirican A; Goksel S
World J Gastroenterol; 2007 Sep; 13(33):4437-44. PubMed ID: 17724798
[TBL] [Abstract][Full Text] [Related]
43. Salivary Tumour Necrosis Factor-α as a Biomarker in Oral Leukoplakia and Oral Squamous Cell Carcinoma.
G D; Nandan SRK; Kulkarni PG
Asian Pac J Cancer Prev; 2019 Jul; 20(7):2087-2093. PubMed ID: 31350970
[TBL] [Abstract][Full Text] [Related]
44. [The p16 methylation in oral leukoplakia and oral squamous cell carcinoma].
Liu HW; Hu BQ; Cao CF
Zhonghua Kou Qiang Yi Xue Za Zhi; 2005 Mar; 40(2):94-7. PubMed ID: 15842853
[TBL] [Abstract][Full Text] [Related]
45. Expression of p16 in oral cancer and premalignant lesions.
Buajeeb W; Poomsawat S; Punyasingh J; Sanguansin S
J Oral Pathol Med; 2009 Jan; 38(1):104-8. PubMed ID: 19192055
[TBL] [Abstract][Full Text] [Related]
46. H3 and H3.3 histone mRNA amounts and ratio in oral squamous cell carcinoma and leukoplakia.
Piscopo M; Campisi G; Colella G; Bilancione M; Caccamo S; Di Liberto C; Tartaro GP; Giovannelli L; Pulcrano G; Fucci L
Oral Dis; 2006 Mar; 12(2):130-6. PubMed ID: 16476033
[TBL] [Abstract][Full Text] [Related]
47. A novel lncRNA LOLA1 may predict malignant progression and promote migration, invasion, and EMT of oral leukoplakia via the AKT/GSK-3β pathway.
Liu W; Yao Y; Shi L; Tang G; Wu L
J Cell Biochem; 2021 Oct; 122(10):1302-1312. PubMed ID: 33969929
[TBL] [Abstract][Full Text] [Related]
48. Microsatellite instability in metaplasia-dysplasia-adenocarcinoma sequence of Barrett esophagus: a retrospective study.
Markoš P; Brčić I; Brčić L; Jakić-Razumović J; Pulanić R
Croat Med J; 2018 Jun; 59(3):100-107. PubMed ID: 29972732
[TBL] [Abstract][Full Text] [Related]
49. Serum metabolomics in oral leukoplakia and oral squamous cell carcinoma.
Sridharan G; Ramani P; Patankar S
J Cancer Res Ther; 2017; 13(3):556-561. PubMed ID: 28862226
[TBL] [Abstract][Full Text] [Related]
50. Repair genes expression profile of MLH1, MSH2 and ATM in the normal oral mucosa of chronic smokers.
Alves MG; Carta CF; de Barros PP; Issa JS; Nunes FD; Almeida JD
Arch Oral Biol; 2017 Jan; 73():60-65. PubMed ID: 27693945
[TBL] [Abstract][Full Text] [Related]
51. Transglutaminase 3 contributes to malignant transformation of oral leukoplakia to cancer.
Wu X; Wang R; Jiao J; Li S; Yu J; Yin Z; Zhou L; Gong Z
Int J Biochem Cell Biol; 2018 Nov; 104():34-42. PubMed ID: 30172723
[TBL] [Abstract][Full Text] [Related]
52. Enhanced detection of microsatellite instability and mismatch repair gene expression in cutaneous squamous cell carcinomas.
Gray SE; Kay EW; Leader M; Mabruk MJ
Mol Diagn Ther; 2006; 10(5):327-34. PubMed ID: 17022696
[TBL] [Abstract][Full Text] [Related]
53. CD133 expression in oral lichen planus correlated with the risk for progression to oral squamous cell carcinoma.
Sun L; Feng J; Ma L; Liu W; Zhou Z
Ann Diagn Pathol; 2013 Dec; 17(6):486-9. PubMed ID: 23911820
[TBL] [Abstract][Full Text] [Related]
54. Promoter hypermethylation of DNA repair genes MLH1 and MSH2 in adenocarcinomas and squamous cell carcinomas of the lung.
Gomes A; Reis-Silva M; Alarcão A; Couceiro P; Sousa V; Carvalho L
Rev Port Pneumol; 2014; 20(1):20-30. PubMed ID: 24360395
[TBL] [Abstract][Full Text] [Related]
55. Application of a non-invasive oral brushing procedure based on bisulfite sequencing of a 13-gene panel to study high-risk OSCC patients.
Gissi DB; Gabusi A; Tarsitano A; Asioli S; Rossi R; Marchetti C; Montebugnoli L; Foschini MP; Morandi L
Cancer Biomark; 2020; 28(4):499-510. PubMed ID: 32568174
[TBL] [Abstract][Full Text] [Related]
56. An immunohistochemical evaluation of podoplanin expression in oral leukoplakia and oral squamous cell carcinoma to explore its potential to be used as a predictor for malignant transformation.
Aiswarya A; Suresh R; Janardhanan M; Savithri V; Aravind T; Mathew L
J Oral Maxillofac Pathol; 2019; 23(1):159. PubMed ID: 31110440
[TBL] [Abstract][Full Text] [Related]
57. Role of TP53 in the progression of pre-malignant and malignant oral mucosal lesions. A follow-up study of 144 patients.
Ogmundsdóttir HM; Björnsson J; Holbrook WP
J Oral Pathol Med; 2009 Aug; 38(7):565-71. PubMed ID: 19473450
[TBL] [Abstract][Full Text] [Related]
58. TWIST and p-Akt immunoexpression in normal oral epithelium, oral dysplasia and in oral squamous cell carcinoma.
Silva BS; Yamamoto FP; Pontes FS; Cury SE; Fonseca FP; Pontes HA; Pinto-Júnior DD
Med Oral Patol Oral Cir Bucal; 2012 Jan; 17(1):e29-34. PubMed ID: 21743395
[TBL] [Abstract][Full Text] [Related]
59. Role of bcl-2 oncoprotein in oral potentially malignant disorders and squamous cell carcinoma: an immunohistochemical study.
Sudha VM; Hemavathy S
Indian J Dent Res; 2011; 22(4):520-5. PubMed ID: 22124045
[TBL] [Abstract][Full Text] [Related]
60. Is there a natural limit of the transformation rate of oral leukoplakia?
Scheifele C; Reichart PA
Oral Oncol; 2003 Jul; 39(5):470-5. PubMed ID: 12747971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
